COPD (Smoker’s) Study

Study Compensation: up to $2350

The P1-COPD-04-INT study is evaluating how switching to a product called the Tobacco Heating System (THS) may impact symptoms and the disease progression of early chronic obstructive pulmonary disease (COPD) in smokers.

• Are between 40 and 65 years of age.
• Have been smoking for at least 10 years.
• Have been smoking a minimum of 10 cigarettes a day for at least the last year.
• Have not used other tobacco and nicotine products apart from cigarettes on a daily basis over the past year.
• Have experienced cough and sputum (symptoms of chronic bronchitis) over the past year OR have been diagnosed with mild-to-moderate COPD.
• Are not pregnant, if you are a female.

• THS and sticks, if you decide to enroll into this group.
• Close monitoring of your health through repeated, detailed check-ups, and medical supervision and care.
• Smoking cessation advice (provided to all study subjects).
• Behavioral support if you chose to stop smoking or to switch to THS.
• Nicotine replacement therapy if you decide to stop smoking and would like to be provided with such therapy.
• Reimbursement for study participation may be available.

Diabetic Neuropathy Study

Study Compensation: up to: $1100

A Phase 2 Study to Evaluate the Safety and Efficacy of RTA 901 in Patients with Diabetic Peripheral Neuropathic Pain.

• Adult male and female subjects ≥ 18 years of age upon study consent.
• Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus at least 1 year prior to Screening.
• Clinical diagnosis of DPNP defined as symptomatic distal symmetric polyneuropathy(secondary to diabetes) in the lower extremities, which may include symptoms of pain that is burning, lancinating, tingling, or shooting (electric shock–like). Pain in the lower extremities may occur with paresthesia or dysesthesia (unpleasant sensations of burning). Neuropathic pain may be accompanied by an exaggerated response to painful stimuli (hyperalgesia)

• Has neuropathy from a cause other than type 1 diabetes mellitus or type 2 diabetes mellitus.
• Has a condition other than DPNP that could confound the assessment of pain (eg, fibromyalgia or regional pain caused by lumbar or cervical compression);
• Hemoglobin A1C > 11% at Screening.
• Diabetic foot ulceration or infection within 90 days prior to Screening.
• Has had more than 1 episode of ketoacidosis or hyperosmolar state requiring hospitalization within 90 days prior to Screening.
• Has had more than 3 episodes of hypoglycemia requiring medical assistance within 90 days prior to Screening.
• Any acute or chronic medical condition, or concurrent therapy (pharmaceutical or otherwise) which, in the opinion of the Investigator could potentially adversely impact subject safety, response to study drug, or interfere with study assessments.
• Clinically significant and severe ophthalmologic disease, including but not limited to retinopathy, or visual field impairment which, in the opinion of the Investigator could potentially preclude enrollment in the study.
• Serum aminotransferase (alanine aminotransferase or aspartate aminotransferase) levels > 1.5× the upper limit of normal at Screening.
• Has HIV or active hepatitis B or C virus infection.

Lung Cancer Study

Compensation: $100(1 visit)

Early Detection of Lung Cancer.

• Diagnostic performance of blood test following up imaging after positive low dose CT Screening for cancer of the lung.
• Adult male and female patient aged 50 to 80.